glp 1 agonists and sglt2 inhibitors SGLT-2 GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease Cardiovascular benefits of SGLT2 inhibitors
Description
PlexusDx supports a precision approach: understanding your metabolic predispositions and working with your healthcare provider to determine whether delaying treatment until weaning is appropriate for your situation
Drawing a conclusion that subcutaneous semaglutide is associated with worsening of DR from this paper alone is thus premature
Most studies were conducted in controlled trials rather than real-world clinical practice
For women in perimenopause and menopause, dosing decisions should follow a structured evaluation
What Is Type 2 Diabetes
Mansur RB, Delgado-Peraza F, Subramaniapillai M, Lee Y, Iacobucci M, Nasri F, et al
